Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
Dr Kaarkuzhali B. Krishnamurthy joins Ethics Talk to discuss her article: “Should Physicians Be Able to Refuse to Care for Patients Insured by Medicare?”
Makenzie Doubek joins Ethics Talk to discuss her article, coauthored with Scott J. Schweikart: “Why Should Physicians Care About What Law Says About Turfing and Dumping Patients?”
Dr Patricia Luck joins Ethics Talk to discuss her article, coauthored with Arman M. Niknafs: “Reasons Not to Turf a Patient Whose ‘Belonging’ in a Hospital Is Unclear.”